Xulu Kutlwano R, Augustine Tanya N
School of Anatomical Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1532. doi: 10.3390/ph15121532.
The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour's capacity to survive, invade and metastasise, amongst other hallmarks of the disease. The use of anticoagulant or antiplatelet drugs in cardiovascular disease lessens thrombotic effects, but the consequences on tumour progression require interrogation. Therefore, this review considered developments in the management of platelet activation pathways (thromboxane, ADP and thrombin), focusing on the use of Aspirin, Clopidogrel and Atopaxar, and their potential impacts on tumour progression. Published data suggested a cautionary tale in ensuring we adequately investigate not only drug-drug interactions but also those unforeseen reciprocal interactions between drugs and their targets within the tumour microenvironment that may act as selective pressures, enhancing tumour survival and progression.
癌症与高凝环境之间的关联已有充分描述。血栓形成并发症不仅是主要的死亡风险因素，而且其潜在的分子结构和功能在促进肿瘤进展中发挥着重要作用，肿瘤进展被定义为肿瘤生存、侵袭和转移的能力以及该疾病的其他特征。在心血管疾病中使用抗凝或抗血小板药物可减轻血栓形成效应，但对肿瘤进展的影响需要深入研究。因此，本综述探讨了血小板激活途径（血栓素、二磷酸腺苷和凝血酶）管理方面的进展，重点关注阿司匹林、氯吡格雷和阿托西班的使用及其对肿瘤进展的潜在影响。已发表的数据警示我们，不仅要充分研究药物相互作用，还要研究药物与其在肿瘤微环境中的靶点之间那些不可预见的相互作用，这些相互作用可能作为选择性压力，增强肿瘤的生存和进展能力。
